Stoke Therapeutics
STOK
70 hedge funds and large institutions have $825M invested in Stoke Therapeutics in 2020 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 24 reducing their positions, and 6 closing their positions.
12,060% more call options, than puts
Call options by funds: $608K | Put options by funds: $5K
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
4% more funds holding
Funds holding: 67 → 70 (+3)
4% more capital invested
Capital invested by funds: $796M → $825M (+$28.4M)
0.45% more ownership
Funds ownership: 105.54% → 105.99% (+0.45%)
29% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 24
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.5M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$7.99M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.25M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$3.42M |
| 5 |
Millennium Management
New York
|
+$3.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$12.2M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$7.78M |
| 3 |
BlackRock
New York
|
-$3.72M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$2.78M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.75M |
STOK Hedge Fund Activity: Q2 2020 in Review
70 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q2 2020, worth a combined $825M — up 3.6% from $796M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new STOK positions and 6 closed out — a net gain of 3 holders — while 17 added to existing stakes and 24 trimmed.
The largest buyer was Vanguard Group, adding an estimated $11.5M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $12.2M sold.
- 70 institutional investors held Stoke Therapeutics (STOK) as of Q2 2020, up from 67 in Q1 2020.
- Funds reported $825M of Stoke Therapeutics stock for Q2 2020, up 3.6% quarter-over-quarter.
- 9 funds opened new Stoke Therapeutics positions in Q2 2020 and 6 closed out, a net change of +3 holders.
- The largest Stoke Therapeutics buyer in Q2 2020 was Vanguard Group, an estimated $11.5M added.
- The largest Stoke Therapeutics seller in Q2 2020 was Janus Henderson Group, an estimated $12.2M sold.
Based on aggregated 13F filings for Q2 2020.